
CagriSema Weight-Loss Results: What the Percentages Mean


CagriSema weight-loss results depend on the trial, treatment regimen and analysis used. The 21.0% average reported for REDEFINE 9 describes 68 weeks under an analysis assuming treatment adherence. It is not a promise that every participant will lose one-fifth of their weight, and it should not be attached to another trial’s 84-week timeline. Start with the study name and analysis, then interpret the percentage.
At Maryland Trim Clinic, we help patients translate research into realistic questions about care. Our medical weight loss program considers meaningful health changes and the ability to sustain treatment, alongside the scale.
Which trial produced the 21% CagriSema result?
CagriSema combines cagrilintide with semaglutide and remains investigational. Its development program includes studies with different doses, populations, comparators, and durations. A result is not fully described by naming the medicine and one percentage.
Novo Nordisk's REDEFINE 9 results announcement reported 21.0% weight reduction with the studied lower-dose CagriSema regimen over 68 weeks under an adherence-focused analysis, compared with 2.0% for placebo. That is a sponsor-reported finding with a specific study context.
REDEFINE 4 asked a different question. It compared CagriSema with tirzepatide over 84 weeks. Its reported primary comparison did not establish CagriSema's noninferiority. The results included different estimates depending on whether the analysis addressed continued treatment or treatment assignment regardless of discontinuation.
It is misleading to take a percentage from one study, a timeline from another, and a safety statement from a third, then present them as one patient journey. The label attached to a number needs to travel with it.
How REDEFINE 1 differs from the 21% headline
In REDEFINE 1, the 68-week CagriSema result was 20.4% under the treatment-policy analysis, compared with 3.0% for placebo. The adherence-focused estimates were 22.7% and 2.3%, respectively. These figures describe a different study and regimen from REDEFINE 9. Keep each estimate paired with its own analysis rather than selecting the largest number from each report.
What does 21% weight loss mean in pounds?
To calculate a hypothetical percentage change, multiply the starting weight by the percentage expressed as a decimal. A 21% reduction from 200 pounds is 42 pounds, leaving 158 pounds. From 250 pounds it is 52.5 pounds, leaving 197.5 pounds. From 300 pounds it is 63 pounds, leaving 237 pounds.
These are arithmetic illustrations, not treatment predictions or recommended goals. They assume exactly the same percentage change at three different starting weights solely to show how the calculation works.
The larger pound change at a higher starting weight does not mean the treatment worked better in that example. The proportional change is identical. Conversely, two people losing the same number of pounds may have different percentage changes because their starting weights differ.
It is also useful to distinguish body weight from body fat. A weight reduction includes changes in multiple tissues and fluids. The percentage on the scale cannot identify the composition of that change.
Why the average is not your personal prediction
An average condenses a range of outcomes into one number. Some participants lose more, some less, and some may experience little benefit or gain weight. The average alone does not reveal how many participants reached a particular threshold or how many stopped treatment.
A response distribution provides more information. Researchers may report the proportions achieving at least 5%, 10%, 15%, or another threshold of weight reduction. Those proportions answer different questions from the mean. Neither should be treated as an individual promise.
A confidence interval addresses uncertainty in an estimated group effect. It is not the range within which every future patient's result will fall. Confusing statistical precision with predictability can make a trial appear more personally certain than it is.
The practical question is whether the evidence supports a reasonable chance of meaningful benefit for someone like you, with acceptable risks and a plan for reassessment. That requires more information than the average.
Treatment-policy versus adherence-focused results
Trials may estimate what happens when people are assigned treatment regardless of interruptions, and what would happen under continued treatment as planned. The first question is closer to the effect of a treatment strategy that includes discontinuation. The second helps describe potential efficacy with ongoing exposure.
Neither analysis should be reduced to a slogan such as real versus fake. Both can be useful when the methods and assumptions are clear. Problems arise when the more favorable number is presented without explaining the question it answers.
Adherence is not just willpower. Symptoms, access, competing illness, and practical demands can affect whether someone remains on a medicine. A treatment that works well under continued use still needs a tolerability and support plan that makes continued use possible.
For a patient, this means asking which result is being quoted and how discontinuation was handled. It does not mean trying to recreate a clinical trial by enduring symptoms that should be evaluated.
Why a trial endpoint is not a weekly weight-loss schedule
Weight change usually does not follow a straight line from the first visit to the final study assessment. The endpoint average does not tell you how much to lose each week. Dividing a trial's total percentage by its number of weeks creates a mathematical average, not a validated treatment schedule.
Periods of faster change, slower change, or stability can occur. Daily readings can also vary with fluid balance, digestion, and measurement conditions. Our guidance on weighing consistently can help keep ordinary fluctuations from becoming a source of unnecessary alarm.
When progress slows, a plateau review is more useful than assuming the next week must compensate for the last. The review should consider the overall trajectory, health markers, eating adequacy, symptoms, and the purpose of treatment.
What a percentage cannot show about your body
A weight result does not tell you whether strength improved, whether movement became easier, or whether nutritional intake remained adequate. It also does not prove a specific change in visceral fat, liver fat, or muscle tissue unless those outcomes were separately measured.
Our 3D body scanning information explains one way to follow body shape and circumference estimates. These measurements should not be used to declare that a medicine preserved muscle or reversed liver disease. Different clinical questions require different measurements.
The nutrition plan needs attention even when weight loss is substantial. Our nutrition counseling and coaching can help address meal adequacy and practical barriers. Weakness, persistent inability to eat, or dehydration should not be accepted as the price of reaching a target percentage.
How to define a useful personal goal
Start with the health problem and the change that would matter in daily life. Examples include improving a clinician-monitored risk factor, moving more comfortably, or establishing a more manageable eating pattern. These goals can coexist with a weight target, but they make the plan less dependent on matching a trial average.
A clinician can help determine whether medication is appropriate and which established option fits the situation. Our GLP-1 treatment page provides background for that conversation. CagriSema research should not be read as a promise that the investigational combination is available through routine care.
Ask in advance what will be monitored, when benefit will be reassessed, and what problems should prompt contact. Also discuss what happens if the medicine becomes difficult to obtain or tolerate. An expected benefit has little practical meaning without a way to sustain the plan.
A checklist for comparing CagriSema trial results

Before treating a percentage as relevant to you, identify the following:
- The exact drug or combination and the regimen studied.
- The participants, including whether they had diabetes or other conditions.
- The comparator and study duration.
- The outcome definition and statistical analysis.
- The range of responses, discontinuation, and important adverse effects.
- Whether the result is a complete publication or a sponsor announcement.
If the headline omits these details, keep the conclusion provisional. The number may be accurate while the implied promise is not.
Bringing the numbers into a care discussion
We can help patients review research claims alongside their own health history and treatment experience. Bring the source of the percentage and the question it raises for you, along with any current medication concerns.
To discuss a realistic plan, contact Maryland Trim Clinic. The aim is meaningful benefit that you can sustain, with adjustments based on your response rather than pressure to reproduce a group average.
Frequently Asked Questions
Does 21% mean that 21% of participants lost weight?
No. It describes the average percentage change in body weight for a specified analysis. The proportion of participants who lost weight is a different measure.
Is the 21% figure a prediction for someone starting at 250 pounds?
No. Multiplying 250 by 0.21 illustrates the arithmetic, giving 52.5 pounds. It does not predict an individual's treatment result.
Does the 21% figure describe an 84-week CagriSema study?
The 21.0% result discussed here came from the reported 68-week REDEFINE 9 analysis. REDEFINE 4 was an 84-week study with different regimens, a different comparator, and different results.
If I lose less than a trial average, has treatment failed?
Not necessarily. Clinical benefit, tolerability, nutrition, function, and your individual goals all matter. Review the overall response with the treating clinician.
Talk Through CagriSema Research
If you want help interpreting trial results in the context of your own goals, reach out to Maryland Trim Clinic to discuss next steps.